Development and characterization of gemcitabine-resistant pancreatic tumor cells - PubMed (original) (raw)
. 2007 Dec;14(12):3629-37.
doi: 10.1245/s10434-007-9583-5. Epub 2007 Oct 2.
Affiliations
- PMID: 17909916
- DOI: 10.1245/s10434-007-9583-5
Development and characterization of gemcitabine-resistant pancreatic tumor cells
Ami N Shah et al. Ann Surg Oncol. 2007 Dec.
Abstract
Background: Pancreatic cancer is an exceptionally lethal disease with an annual mortality nearly equivalent to its annual incidence. This dismal rate of survival is due to several factors including late presentation with locally advanced, unresectable tumors, early metastatic disease, and rapidly arising chemoresistance. To study the mechanisms of chemoresistance in pancreatic cancer we developed two gemcitabine-resistant pancreatic cancer cell lines.
Methods: Resistant cells were obtained by culturing L3.6pl and AsPC-1 cells in serially increasing concentrations of gemcitabine. Stable cultures were obtained that were 40- to 50-fold increased in resistance relative to parental cells. Immunofluorescent staining was performed to examine changes in beta-catenin and E-cadherin localization. Protein expression was determined by immunoblotting. Migration and invasion were determined by modified Boyden chamber assays. Fluorescence-activated cell sorting (FACS) analyses were performed to examine stem cell markers.
Results: Gemcitabine-resistant cells underwent distinct morphological changes, including spindle-shaped morphology, appearance of pseudopodia, and reduced adhesion characteristic of transformed fibroblasts. Gemcitabine-resistant cells were more invasive and migratory. Gemcitabine-resistant cells were increased in vimentin and decreased in E-cadherin expression. Immunofluorescence and immunoblotting revealed increased nuclear localization of total beta-catenin. These alterations are hallmarks of epithelial-to-mesenchymal transition (EMT). Resistant cells were activated in the receptor protein tyrosine kinase, c-Met and increased in expression of the stem cell markers CD (cluster of differentiation)24, CD44, and epithelial-specific antigen (ESA).
Conclusions: Gemcitabine-resistant pancreatic tumor cells are associated with EMT, a more-aggressive and invasive phenotype in numerous solid tumors. The increased phosphorylation of c-Met may also be related to chemoresistance and EMT and presents as an attractive adjunctive chemotherapeutic target in pancreatic cancer.
Comment in
- Gemicitabine resistence and mesenchymal phenotype.
Inamoto T, Azuma H, Katsuoka Y. Inamoto T, et al. Ann Surg Oncol. 2009 May;16(5):1435-6. doi: 10.1245/s10434-008-0309-0. Epub 2009 Jan 29. Ann Surg Oncol. 2009. PMID: 19184229 No abstract available.
Similar articles
- Identification and Clinical Significance of Pancreatic Cancer Stem Cells and Their Chemotherapeutic Drug Resistance.
Kuo YC, Kou HW, Hsu CP, Lo CH, Hwang TL. Kuo YC, et al. Int J Mol Sci. 2023 Apr 15;24(8):7331. doi: 10.3390/ijms24087331. Int J Mol Sci. 2023. PMID: 37108495 Free PMC article. - Paracrine HGF promotes EMT and mediates the effects of PSC on chemoresistance by activating c-Met/PI3K/Akt signaling in pancreatic cancer in vitro.
Xu J, Liu S, Yang X, Cao S, Zhou Y. Xu J, et al. Life Sci. 2020 Dec 15;263:118523. doi: 10.1016/j.lfs.2020.118523. Epub 2020 Oct 8. Life Sci. 2020. PMID: 33039386 - Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells.
Du Z, Qin R, Wei C, Wang M, Shi C, Tian R, Peng C. Du Z, et al. Dig Dis Sci. 2011 Mar;56(3):741-50. doi: 10.1007/s10620-010-1340-0. Epub 2010 Aug 4. Dig Dis Sci. 2011. PMID: 20683663 - Heat-shock protein 27 plays the key role in gemcitabine-resistance of pancreatic cancer cells.
Kuramitsu Y, Wang Y, Taba K, Suenaga S, Ryozawa S, Kaino S, Sakaida I, Nakamura K. Kuramitsu Y, et al. Anticancer Res. 2012 Jun;32(6):2295-9. Anticancer Res. 2012. PMID: 22641665 Review. - [Pancreatic cancer--mechanisms of chemoresistance].
Borowa-Mazgaj B. Borowa-Mazgaj B. Postepy Hig Med Dosw (Online). 2016 Mar 4;70:169-79. doi: 10.5604/17322693.1196387. Postepy Hig Med Dosw (Online). 2016. PMID: 26943314 Review. Polish.
Cited by
- Recent nanotechnology advancements to treat multidrug-resistance pancreatic cancer: Pre-clinical and clinical overview.
Alshememry AK, Alsaleh NB, Alkhudair N, Alzhrani R, Alshamsan A. Alshememry AK, et al. Front Pharmacol. 2022 Aug 24;13:933457. doi: 10.3389/fphar.2022.933457. eCollection 2022. Front Pharmacol. 2022. PMID: 36091785 Free PMC article. Review. - MACC1: A potential molecule associated with pancreatic cancer metastasis and chemoresistance.
Wang G, Kang MX, Lu WJ, Chen Y, Zhang B, Wu YL. Wang G, et al. Oncol Lett. 2012 Oct;4(4):783-791. doi: 10.3892/ol.2012.784. Epub 2012 Jul 2. Oncol Lett. 2012. PMID: 23205101 Free PMC article. - PLEK2 promotes migration and invasion in pancreatic ductal adenocarcinoma by MMP1 through IL-17 pathway.
Cheng K, Chen Q, Chen Z, Cai Y, Cai H, Wu S, Gao P, Cai Y, Wu Z, Zhou J, Peng B, Wang X. Cheng K, et al. Mol Cell Biochem. 2024 Aug 9. doi: 10.1007/s11010-024-05078-x. Online ahead of print. Mol Cell Biochem. 2024. PMID: 39117976 - MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine.
Liang C, Yu XJ, Guo XZ, Sun MH, Wang Z, Song Y, Ni QX, Li HY, Mukaida N, Li YY. Liang C, et al. Oncotarget. 2015 Jun 10;6(16):14440-55. doi: 10.18632/oncotarget.3885. Oncotarget. 2015. PMID: 25971209 Free PMC article. - Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
Brandes F, Schmidt K, Wagner C, Redekopf J, Schlitt HJ, Geissler EK, Lang SA. Brandes F, et al. BMC Cancer. 2015 Feb 19;15:71. doi: 10.1186/s12885-015-1064-9. BMC Cancer. 2015. PMID: 25884642 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous